Repaglinide: a review of its use in type 2 diabetes mellitus.
about
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitusManagement of diabetes mellitus type-2 in the geriatric population: Current perspectivesUpdate on the treatment of type 2 diabetes mellitusInsulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.Optimal therapy of type 2 diabetes: a controversial challengeBilayer matrix tablets for prolonged actions of metformin hydrochloride and repaglinideA variant of PSMD6 is associated with the therapeutic efficacy of oral antidiabetic drugs in Chinese type 2 diabetes patients.Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptinTrimeprazine increases IRS2 in human islets and promotes pancreatic β cell growth and function in miceNoninsulin glucose-lowering agents for the treatment of patients on dialysis.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus.Pharmacogenomics of glinides.Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study.Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.Investigational insulin secretagogues for type 2 diabetes.Impact of chronic unpredicted mild stress-induced depression on repaglinide fate via glucocorticoid signaling pathway.Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.Enantioselective Decarboxylative Arylation of α-Amino Acids via the Merger of Photoredox and Nickel Catalysis.PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers.Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.Identification, isolation, and synthesis of seven novel impurities of anti-diabetic drug Repaglinide.The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy.Comparison of daytime 12-hour metabolic profiles after treatment with repaglinide and gliclazide in type 2 diabetes
P2860
Q24185970-1B2AC58F-7951-41AD-829D-9B5C69A27D36Q26999670-5617B8FE-A3AD-4E5A-B74D-6DB50E6C0ADBQ28073342-C2B953A7-CF5C-4B43-A8C7-8D82EF7711AAQ30243879-30E92590-F9F4-460D-A0B6-1505A2B1562EQ33577712-DCF8370B-AA5A-407F-92B9-CCE5404EB184Q35209974-873923D4-EE21-4C48-83D9-59226D28B138Q35664025-8E03CE9C-F871-448A-AAB6-6A32E19A7C79Q36637965-4CDFDC6A-DB26-45A3-8BC9-2C6B9DA152F0Q36862098-5C7351DE-4610-4DFC-A0A2-B6B5338D8ECCQ38077451-15DA7FD1-3230-4075-BB9B-E789A54B9F08Q38086611-C0E3E7EA-4833-49B6-B2AC-4AB32F3BBE5DQ38199526-D63E0CA9-9FA6-468F-9D37-36ED944A9B0CQ38259933-65F7E6D7-E583-4D5D-AF42-B88785E2E007Q38307994-B066963F-DE0E-4C57-8263-52587DD4FC9BQ38437256-C4B7189C-23A0-44F6-AA9A-1B3B02080619Q38606170-6771A04E-87B1-45E0-8B9A-9DDF946F6ADDQ38735419-50CCFCED-462F-4CF2-9B93-58E7A67F7508Q38748706-A18296AB-AA07-43F0-B0D6-0B1EAC07FB97Q39212609-29FE6CCE-1691-4B64-86CA-423F8C39B24DQ41295730-69D8E666-FC5D-43A7-A9CA-0863179F0049Q44755603-5CDDEBBB-DE3B-4354-8FAA-5438E5ED467FQ46207930-A5A62885-8FCF-41A9-9390-4DECA3B4B689Q48260378-D18A3052-9A3D-436C-8442-FB2C705FEE07Q49806629-5D62AC51-DBD1-47CE-B0A7-B13D5BDFD005Q57951374-B97B01C1-B648-404F-A5B7-FE59E82A7B18
P2860
Repaglinide: a review of its use in type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Repaglinide: a review of its use in type 2 diabetes mellitus.
@en
Repaglinide: a review of its use in type 2 diabetes mellitus.
@nl
type
label
Repaglinide: a review of its use in type 2 diabetes mellitus.
@en
Repaglinide: a review of its use in type 2 diabetes mellitus.
@nl
prefLabel
Repaglinide: a review of its use in type 2 diabetes mellitus.
@en
Repaglinide: a review of its use in type 2 diabetes mellitus.
@nl
P2860
P1433
P1476
Repaglinide: a review of its use in type 2 diabetes mellitus.
@en
P2860
P304
P356
10.2165/11207600-000000000-00000
P577
2012-01-01T00:00:00Z
P6179
1008475365